LAST WEEK LEFT of our holiday sale! Get your discounted market research reports now.
The Alpha
Mannosidosis Global Market Report 2022-31 by The Business Research Company
describes and explains the global alpha mannosidosis market and covers 2016 to
2021, termed the historic period, and 2022 to 2026, termed the forecast period,
along with further forecasts for the period 2026-2031. The report evaluates the
market across each region and for the major economies within each region.
The Alpha
Mannosidosis Global Market Opportunities And Strategies Report covers alpha
mannosidosis market drivers, alpha mannosidosis market trends, alpha
mannosidosis market segments, alpha mannosidosis market growth rate, alpha
mannosidosis market major players, and alpha mannosidosis market size.
View more on the Alpha Mannosidosis Market Report:
https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market
The alpha
mannosidosis market report focuses particularly on identifying the trends,
opportunities, and strategies that can lead to success. O&S reports are
available off the shelf and can be delivered to clients on the day of purchase.
The Alpha
Mannosidosis Global Market Opportunities And Strategies Report is the most
comprehensive report available on this market and will help gain a truly global
perspective as it covers 60 geographies in detail. The chapter on the impact of
COVID-19 gives valuable insights on supply chain disruptions, logistical
challenges, and other economic implications of the virus on the market. The
chapter also covers markets which have been positively affected by the
pandemic.
Request for the report sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5537&type=smp
Alpha
Mannosidosis market trends include:
The use of enzyme
replacement therapy is increasingly gaining traction in the alpha mannosidosis
market. Lamzede (velmanase alfa) is a long-term enzyme replacement therapy in
adults, adolescents, and children to help treat mild to moderate forms of
alpha-mannosidosis. It is a recombinant human alpha-mannosidase developed as an
intravenous enzyme replacement therapy (ERT) to administer the medicine into
the bloodstream in order to replace the function of the deficient enzyme in the
body. The therapy aims to normalize oligosaccharide levels in the body, which
ultimately prevents the progression of the disease and the formation of
abnormalities. For instance, as per a study conducted in 2018, the benefits of
Lamzede were assessed in 25 patients in a multi-centre, randomized,
double-blind, placebo-controlled parallel group trial over 52 weeks showed an
improvement in exercise capacity, a decrease of serum oligosaccharide to normal
levels, and pulmonary function in certain patients.
The report covers
the alpha mannosidosis market segments:
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy
(ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy
2) By Indication:
Type I, Type II, Type III
3) By End-User:
Hospitals, Specialty Clinics
About The Business Research Company:
The Business
Research Company is a market intelligence firm that excels in company, market,
and consumer research. Located globally it has specialist consultants in a wide
range of industries including manufacturing, healthcare, financial services,
chemicals, and technology. It has offices in the UK, the US and India and
a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Check us out on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
No comments:
Post a Comment